Drug intelligence / Profile preview

Sanghuangyin

Development stage: Unknown
Lead developer: Zhejiang Province Cancer Hospital
Administration: Oral

Overview

Compound Sanghuangyin is a Traditional Chinese Medicine (TCM) formulation primarily derived from the medicinal fungus *Phellinus linteus* (Sanghuang). It is developed by Zhejiang Cancer Hospital as a hepatoprotective agent for patients with primary liver cancer (hepatocellular carcinoma). The drug is specifically investigated for its ability to mitigate acute liver injury following interventional procedures such as Transarterial Chemoembolization (TACE) or Hepatic Arterial Infusion Chemotherapy (HAIC). Administered orally, it is intended to complement standard hepatoprotective therapies by leveraging the anti-inflammatory and antioxidant properties associated with *Phellinus linteus* extracts.

Other names: SanghuangyinCompound SanghuangyinFufang Sanghuangyin

Beyond the preview

Go deeper on Sanghuangyin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanghuangyin.

Explore the full profile